CAS: 174022-42-5; Bevirimat
该化合物是一种抗逆转录病毒化合物,主要为治疗艾滋病毒的潜在用途而进行调查,属于被称为成熟抑制剂的一类药物,它干扰了艾滋病毒的成熟过程,从而防止了病毒传染.Bevirimat的化学结构包括碳,氢和氧原子的复杂安排,有助于其独特的特性和行动机制.它通常通过口述方式进行,并在各种临床环境中研究其效力.Bevirimat的机制涉及到艾滋病毒的加格蛋白,这对病毒的成熟和组装至关重要.虽然它在临床试验中表现出希望,但由于抗药性的出现和需要进一步研究以充分理解其长期功效和安全情况,其使用受到限制.总的来说,Bevirimat是目前努力发展有效的艾滋病毒/艾滋病治疗的一个重要研究领域.
- 英文名称Bevirimat
- 中文名称贝韦立马
- IUPAC名称(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-((3-carboxy-3-methylbutanoyl)oxy)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysene-3a-carboxylic acid
- CAS编号174022-42-5
- MFCD编号:MFCD00954243
- FDA UNII编号:S125DW66N8
- 分子式:C36H56O6分子量:584.83
- 产品CID: 889040
- 同类组份化合物CAS174022-42-5 (free acid)823821-85-8 (dimeglumine)
- 产品分类生物化工 → 生化试剂 → 激动剂抑制剂
物理性质
- 熔点>263°C (分解)
- 沸点662.7±40.0 °C(预测)
- 闪点197.7±20.8 °C
- 密度1.13±0.1 g/cm3(预测)
- pKa:4.48±0.28(预测)
- PSA:100.9
- LogP:9.1
- 溶解性Acetonitrile (Slightly), Methanol (Very Slightly, Heated, Sonicated)
- 外观形态白色至类白色固体
- 储存条件防潮, -20°C 冰箱, 在惰性气其中
- 产品应用该化合物是一种抗艾滋病毒药物,它来自一种贝丁酸类化合物,最初从中国草药CLUVIFLORUM 中分离出来,据信通过一种新颖机制,即所谓的成熟抑制剂来抑制艾滋病毒.像蛋白抑制剂, BEVIRIMANT 和其他发育抑制剂一样,干扰新转化的艾滋病毒多蛋白前体(GAG)的蛋白质加工. BEVIRIMAT通过具体禁止SP1空间蛋白(CA)的甲虫蛋白分离来防止这种病毒复制.
MSDS等安全信息
- 警示词warning
- 危险描述H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
- 防范说明P264Thoroughly clean after treatmentP280Wear protective gloves/Wear protective clothing/Wear protective goggles/Wear a protective maskP305If it enters the eyesP351Rinse carefully with water for a few minutesP338Remove the contact lens(If any)And easy to operate,Continue flushingP337If eye irritation persistsP313Obtain medical advice/care
- 安全声明H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
上下游产品
白桦脂酸 Betulinic Acid 472-15-1路路通酸 Betulonic Acid 4481-62-3
白桦脂醇 Betulin 473-98-3
合成工艺路线路线简述
📜白桦脂酸 以70%的收率获得贝韦立马
参考文献:Betulinic Acid And Dihydrobetulinic Acid Derivatives And Uses Therefor
标题:Betulinic Acid And Dihydrobetulinic Acid Derivatives And Uses Therefor
摘要:根据本发明,一些藿醇酸和二氢藿醇酸酰基衍生物已被发现具有强大的抗hiv活性.在藿醇酸和二氢藿醇酸的c.Sub.3-羟基上引入一个c.Sub.2-C.Sub.20取代或未取代的酰基团,可产生相应的3-O-酰基衍生物.本发明的化合物具有以下公式:##str1## 其中r可以是一个单羧酰基或双羧酰基,取代或未取代,碳原子数约为2至20个,而r'可以是氢或一个c.Sub.2-C.Sub.10取代和未取代的烷基或芳基团.
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2905122000-异丙醇
2905399002-1,4-丁二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2009131714-A1
优先权日:2005-06-08
标题:Synthesis of betulonic and betulinic aldehydes
发明人：KRASUTSKY PAVEL A; MUNSHI KALYAN
权利人:KRASUTSKY PAVEL A; MUNSHI KALYAN
摘要:The present invention provides for methods of selectively converting betulin to betulonic aldehyde. The present invention also provides for methods of selectively converting 3-substituted triterpen-28-ols to the corresponding 3-substituted triterpen-28-carboxaldehydes. Additionally, the present invention provides for methods of preparing betulonic aldehyde, betulonic acid, betulinic acid, and corresponding 3-substituted triterpenes.
专利号:US-9994550-B2
优先权日:2014-01-07
标题 :Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
发明人：WAGMAN ALLAN S; JOHNSON RUSSELL J; ZAHARIA CRISTIANA A; CAI HAIYING; HU LILY W; DUKE GREG; OHOL-GUPTA YAMINI; HEUER TIMOTHY; O'FARRELL MARIE
权利人:3 V BIOSCIENCES INC
摘要:Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by dysregulation of a fatty acid synthase pathway by the administration of such compounds.
专利号:US-2024400552-A1
优先权日:2016-11-11
标题 :Heterocyclic modulators of lipid synthesis
发明人：BUCKLEY DOUGLAS I; DUKE GREGORY; WAGMAN ALLAN S; EVANCHIK MARC; MCDOWELL ROBERT S
权利人:SAGIMET BIOSCIENCES INC
摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by dysregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).
专利号:US-11622968-B2
优先权日:2011-03-08
标 题:Heterocyclic modulators of lipid synthesis
发明人：BUCKLEY DOUGLAS; DUKE GREGORY; WAGMAN ALLAN S; EVANCHIK MARC; MCDOWELL ROBERT S
权利人:SAGIMET BIOSCIENCES INC
摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).
专利号:US-10226449-B2
优先权日:2013-12-20
标 题:Heterocyclic modulators of lipid synthesis and combinations thereof
发明人：HEUER TIMOTHY SEAN; OSLOB JOHAN D; MCDOWELL ROBERT S; JOHNSON RUSSELL; YANG HANBIAO; EVANCHIK MARC; ZAHARIA CRISTIANA A; CAI HAIYING; HU LILY W; DUKE GREGORY; OHOL-GUPTA YAMINI; O'FARRELL MARIE
权利人:3 V BIOSCIENCES INC
摘要:Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by dysregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.
专利号:US-9624173-B2
优先权日:2011-03-08
标题 :Heterocyclic modulators of lipid synthesis
发明人：OSLOB JOHAN D; MCDOWELL ROBERT S; JOHNSON RUSSELL; YANG HANBIAO; EVANCHIK MARC; ZAHARIA CRISTIANA A; CAI HAIYING; HU LILY W
权利人:3-V BIOSCIENCES INC
摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Martin DE, Salzwedel K, Allaway GP. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13. doi: 10.1177/095632020801900301. 12(9):940. doi: 10.3390/v12090940.
3: Martin DE, Blum R, Doto J, Galbraith H, Ballow C. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers. Clin Pharmacokinet. 2007;46(7):589-98. doi: 10.2165/00003088-200746070-00004. 24(5):669-73. doi: 10.1097/QAD.0b013e32833160fa.
11:37. doi: 10.1186/1471-2105-11-37.
合成参考文献
参考文献:10.1097/qad.0b013e328331c83b
摘要:Wainberg MA, Albert J. Can the further clinical development of bevirimat be justified AIDS. 2010 Mar 13;24(5):773–4. doi: 10.1097/qad.0b013e328331c83b.
📝 需求与反馈
尽可能描述清楚需求与问题信息
